Innovative Approaches to Alzheimer's Disease Clinical Trials
Join us for an engaging discussion featuring prominent thought leaders from industry and academia who will explore ground-breaking innovations transforming clinical trials for Alzheimer’s Disease. This event focuses on the significant impacts of both at-home and clinical innovations using digital biomarkers, aiming to parallel how advancements in oncology have reshaped cancer treatment strategies. Experts will address the benefits of employing longitudinal EEG data in synchronization with behavioral assessments to streamline trial designs, facilitating faster development of effective therapies for central nervous system disorders.
Key Insights from the Panel Discussion
The exploration of Alzheimer’s clinical trials is witnessing incredible advancements, especially in the use of real-world longitudinal data collection. Panelists will share critical findings from innovative studies like CNS-101, which were recently unveiled at major conferences. These insights will emphasize the importance of data in shaping future research strategies.
Meet the Expert Panelists
Our expert panel includes:
- Dr. Ruth McKernan, FMEdSci CBE, who serves as the Operating Partner at SV Health Investors and also holds the position of CEO at Draig Therapeutics, alongside her role as Chair at Cumulus Neuroscience.
- Professor James Rowe, BA BMBCh FRCP PhD, who directs the prestigious Cambridge Centre for Frontotemporal Dementia and Related Disorders at the University of Cambridge and is the Chief Investigator for CNS-101.
- Bryan J. Hansen, PhD, a Pharma Neuroscientist known for his technological innovations in the field.
- Brian Murphy, PhD, Co-Founder and Chief Scientific Officer at Cumulus Neuroscience.
Progress in Clinical Trial Designs
The ongoing CNS-101 study has been meticulously designed in partnership with ten leading pharmaceutical companies and utilizes the NeuLogiq® Platform. This platform combines various assessments, from passive EEGs to naturalistic language markers, effectively tracking the progression of Alzheimer’s disease. Evidence has shown that at-home assessments yield more accurate measurements than the traditional Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 13), enabling improved monitoring capabilities.
Shifting from snapshot evaluations conducted solely in clinics, the inclusion of digital endpoints allows for real-world monitoring that accurately tracks a patient’s cognitive performance day-to-day, providing a more holistic view of their health over time. This data representation is crucial for understanding the progression of Alzheimer’s disease.
Enhancing Trial Strategies with Digital Biomarkers
Panelists will delve into how integrating digital biomarkers can revolutionize clinical trial architectures, boosting sensitivity, objectivity, and scalability while placing a greater emphasis on the patient's experience. The potential of digital endpoints will be evaluated in terms of their discriminative power compared to conventional measurement practices currently employed in clinical studies.
Ultimately, the discussion aims to showcase how the transition to remote, real-world data collection methods can result in more streamlined trial designs, expedite the development of powerful CNS therapies, and significantly impact the millions worldwide living with Alzheimer’s disease.
Register for the Upcoming Webinar
Don’t miss the chance to be part of this transformative conversation! Register now for this virtual panel discussion set to take place at a convenient time for all interested parties. This session will emphasize how digital endpoints are revolutionizing Alzheimer’s disease clinical trials and aiding in more effective treatment solutions.
About Xtalks
Xtalks, powered by Honeycomb Worldwide Inc., stands out as a premier provider of educational webinars and digital content tailored for the life sciences, food, healthcare, and medical device sectors. Each year, Xtalks attracts thousands of industry professionals seeking valuable insights and updates on important developments in their fields. Dedicated to enhancing knowledge sharing, Xtalks webinars provide perspectives from industry leaders alongside critical discussions on pressing challenges.
For further details or inquiries about hosting a webinar with Xtalks, reach out to us directly.
Frequently Asked Questions
What topics will be discussed in the expert panel?
The panel will focus on innovations in clinical trials for Alzheimer's Disease, highlighting digital biomarkers and longitudinal data collection.
Who are the featured panelists?
The panelists include Dr. Ruth McKernan, Professor James Rowe, Bryan J. Hansen, and Brian Murphy.
How can digital biomarkers enhance clinical trial outcomes?
Digital biomarkers can improve sensitivity and scalability in trials, providing more accurate and real-time insights into patient health and disease progression.
What is the purpose of the CNS-101 study?
CNS-101 aims to track Alzheimer's disease progression using innovative multimodal assessment tools.
How can I participate in the webinar?
Interested individuals can register for the virtual webinar to learn about how innovations in clinical trials are shaping the future of Alzheimer’s research.
